SCHEMBL13615244

SCHEMBL13615244

Cc1cc(C(C)(C)C)ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NHERF1 O14745 1/20 0.65
MCL1 Q07820 5/20 0.64
HPGD P15428 1/20 0.64
TSHR P16473 1/20 0.64
FBP1 P09467 1/20 0.57
BRD4 O60885 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.53
ACLY P53396 1/20 0.53
HSD11B1 P28845 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B2 P37059 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CDK1 P06493 1/20 0.50
CCNB1 P14635 1/20 0.50
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
CDK7 P50613 1/20 0.50
CCNH P51946 1/20 0.50
CCNA1 P78396 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13852847 0.89 ACLY (0.53) NHERF1MCL1HPGDTSHRFBP1
SCHEMBL13615259 0.86 MCL1 (0.62) NHERF1MCL1HPGDTSHRL3MBTL1
SCHEMBL13852823 0.84 MCL1 (0.59) NHERF1MCL1BRD4L3MBTL1ACLY
SCHEMBL13852833 0.83 HSD17B2 (0.63) HSD17B2ALDH1A1
SCHEMBL13629407 0.81 NHERF1 (0.62) NHERF1MCL1HPGDTSHRBRD4
SCHEMBL13615239 0.80 HSD17B2 (0.52) ACLYHSD17B2ALDH1A1
SCHEMBL13852821 0.80 PKM (0.56) HSD17B2ALDH1A1EDNRBEDNRA
SCHEMBL15318105 0.79 NHERF1 (1.00) NHERF1MCL1HPGDTSHRBRD4
SCHEMBL29351587 0.79 NHERF1 (1.00) NHERF1MCL1HPGDTSHRBRD4
SCHEMBL13615292 0.79 MCL1 (0.57) MCL1L3MBTL1ACLYMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK NHERF1 3712/4885MCL1 786/4885HPGD 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.